Hanmi Pharm. Co., Ltd.

Jin Cheul Kim

Jae Hyun Park

Yong Il Kim

Jong Soo Woo

Yo Han Kim

Kyeong Soo Kim

Jung Hyun Cho

Young Keun Choi

Caleb Hyung Min Park

Myeong Ki Jung

Seung Jun Lee

Caleb Hyung Park

Jae Ho Kim

Benjamin Joon Lee

Hyung Seo Kim

An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.

Oral solid formulation containing irinotecan and method of preparing the same

Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size d(0.9) for the bottom 90% is about 10 &#x3bc;m or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.

Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.

Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant

Growing community of inventors

Eunpyeong-gu, South Korea

Jin Cheul Kim